home All News open_in_new Full Article

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended

MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency, for the treatment of Parkinson’s disease (PD), post-encephalitic […]


today 1 week ago attach_file Society

attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Society
attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Transport
attach_file Other
attach_file Other
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other


ID: 4032136381
Add Watch Country

arrow_drop_down